Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • AIM ImmunoTech News

    0,42 $ +1,97% +0,0081 $
    In : 0,3922 € | 15:30:00 Uhr AMEX aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PREX
    ISIN: US00901B1052
    US-Symbol: AIM
    Typ: Aktie

    AIM ImmunoTech News

    29.04.24 - GlobeNewswire
    AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
    Next safety cohort to begin escalated dosing soon
    10.04.24 - GlobeNewswire
    AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
    OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM”) today announced top-line interim data indicating that combining Ampligen ...
    02.04.24 - GlobeNewswire
    AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-​value indications
    26.03.24 - GlobeNewswire
    AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
    OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) announced today that management will host a conference ...
    25.03.24 - GlobeNewswire
    AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
    Data demonstrate compelling evidence of the immune-​stimulatory properties linked to TLR-3 activation through Ampligen
    07.03.24 - GlobeNewswire
    AIM ImmunoTech Announces Launch of CEO Corner Platform
    CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress
    29.02.24 - GlobeNewswire
    AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
    Company continues progress across Ampligen ® clinical development programs
    14.02.24 - GlobeNewswire
    AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
    Phase 1b portion of the study expected to be completed within six months
    24.01.24 - GlobeNewswire
    AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
    Subject enrollment is expected in Q1 2024
    22.01.24 - GlobeNewswire
    AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
    First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands
    10.01.24 - GlobeNewswire
    AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
    First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands
    03.01.24 - PR Newswire
    Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
    Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied PR Newswire
    27.11.23 - GlobeNewswire
    AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
    Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039
    15.11.23 - GlobeNewswire
    AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
    – Highlights continued execution across Ampligen ® clinical development programs
    09.11.23 - GlobeNewswire
    AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
    OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”), announced today that management will host a conference ...
    21.10.23 - PR Newswire
    AIMIA ANNOUNCES CLOSING OF PRIVATE PLACEMENT
    AIMIA ANNOUNCES CLOSING OF PRIVATE PLACEMENT Canada NewsWire
    17.10.23 - GlobeNewswire
    AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
    OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC ...
    27.09.23 - PR Newswire
    Kognitiv Launches AI-Native Kognitiv Ignite: Revolutionary Outcome-Based Customer Engagement Solution
    Kognitiv Launches AI-Native Kognitiv Ignite: Revolutionary Outcome-​Based Customer Engagement Solution PR Newswire
    11.09.23 - GlobeNewswire
    AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
    Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at ...
    15.08.23 - GlobeNewswire
    AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
    – Continued operational execution across pipeline towards multiple clinical and regulatory value-​driving milestones expected in the second half of 2023

    Newssuche

    Videos

    newspaper
    09:15 Uhr -2,46%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »